Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 781-791

  Scott, Stuart A ^a   Khasawneh, Rame ^a   Peter, Inga ^a   Kornreich, Ruth ^a   Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Allele frequencies; CYP2C9; CYP4F2; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; DNA; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

AFRICAN AMERICAN; ARTICLE; ASHKENAZI JEWISH; ASIAN; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; ALLELE; ANCESTRY GROUP; BLOOD CLOTTING; DRUG EFFECTS; GENETIC SCREENING; GENETICS; STATISTICS AND NUMERICAL DATA;

ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DNA; ETHNIC GROUPS; GENE FREQUENCY; GENETIC TESTING; HUMANS; MIXED FUNCTION OXYGENASES; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 77952927473     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.49     Document Type: Article

References (38)

1. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7(2), 99-111 (2007).
2. Limdi NA, Veenstra DL: Warfarin pharmacogenetics. Pharmacotherapy 28(9), 1084-1097 (2008).
3. Schelleman H, Limdi NA, Kimmel SE: Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9(9), 1331-1346 (2008).
4. Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1 Suppl.), S8-S21 (2001).
5. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
6. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
7. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
8. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
9. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large infuence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
10. Takeuchi F, Mcginnis R, Bourgeois S et al.: A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
11. Borgiani P, Ciccacci C, Forte V et al.: CYP4F2 genetic variant (rs2108622) signifcantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2), 261-266 (2009).
12. Mcdonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE: CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75(6), 1337-1346 (2009).
13. Zhang JE, Jorgensen AL, Alfrevic A et al.: Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19(10), 781-789 (2009).
14. Pautas E, Moreau C, Gouin-Thibault I et al.: Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87(1), 57-64 (2010).
15. Carlini EJ, Raftogianis RB, Wood TC et al.: Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11(1), 57-68 (2001).
16. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3(2), 229-243 (2002).
17. Scott SA, Edelmann L, Kornreich R, Desnick RJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82(2), 495-500 (2008).
18. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ: CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
19. Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ: CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 8(7), 721-730 (2007).
20. Sim SC, Ingelman-Sundberg M: The Human Cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol. Biol. 320, 183-191 (2006).
21. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
22. Kirchheiner J, Brockmoller J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77(1), 1-16 (2005).
23. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79(3), 197-205 (2006).
24. Lee MT, Chen CH, Chuang HP et al.: VKORC1 haplotypes in fve East-Asian populations and Indians. Pharmacogenomics 10(10), 1609-1616 (2009).
25. Cavallari LH, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA: Predictors of unstable anticoagulation in African Americans. J. Thromb. Thrombolysis 27(4), 430-437 (2009).
26. Snow V, Qaseem A, Barry P et al.: Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 146(3), 204-210 (2007). (Pubitemid 351650634)
27. White RH: The epidemiology of venous thromboembolism. Circulation 107(23 Suppl. 1), I4-I8 (2003).
28. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, Mcleod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91(1), 87-94 (2004).
29. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006).
30. Schelleman H, Chen J, Chen Z et al.: Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84(3), 332-339 (2008).
31. Langley MR, Booker JK, Evans JP, Mcleod HL, Weck KE: Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J. Mol. Diagn. 11(3), 216-225 (2009).
32. Kimmel SE, Christie J, Kealey C et al.: Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 8(1), 53-60 (2008).
33. Imai J, Ieiri I, Mamiya K et al.: Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic ana lysis of the CYP2C9 locus. Pharmacogenetics 10(1), 85-89 (2000).
34. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identifcation of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14(7), 465-469 (2004).
35. Bae JW, Kim HK, Kim JH et al.: Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60(4), 418-422 (2005).
36. Cavallari LH, Langaee TY, Momary KM et al.: Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
37. Perez-Andreu V, Roldan V, Anton AI et al.: Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113(20), 4977-4979 (2009).
38. Teichert M, Eijgelsheim M, Rivadeneira F et al.: A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18(19), 3758-3768 (2009).